Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer
2011 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 22, no 2, 369-375 p.Article in journal (Refereed) Published
Background: The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment. Patients and methods: One hundred and twenty patients were included. Blood samples were collected before treatment and 3 weeks later before the next treatment cycle. Plasma TIMP-1 and serum CEA levels were correlated to treatment outcome. Results: No significant associations between baseline TIMP-1 or CEA levels and best response to treatment or progression-free survival (PFS) could be demonstrated. In contrast, high baseline plasma TIMP-1 levels were associated with poor overall survival (OS), P = 0.008, hazard ratio (HR) = 1.80 [95% confidence interval (CI): 1.17-2.78]. Furthermore, increase in TIMP-1 levels from baseline to immediately before the second cycle of chemotherapy had a significant negative effect on survival (P = 0.03, HR = 1.30, 95% CI: 1.02-1.65) while a decrease in TIMP-1 was significantly associated with a higher objective response rate (P = 0.03). Conclusions: Both high baseline and subsequent increase in TIMP-1 levels were associated with shorter OS in patients with mCRC receiving XELOX as first-line treatment, whereas baseline TIMP-1 levels were not associated with response or PFS following XELOX treatment.
Place, publisher, year, edition, pages
2011. Vol. 22, no 2, 369-375 p.
biomarkers, metastatic colorectal cancer, overall survival, progression-free survival, response, XELOX
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-149080DOI: 10.1093/annonc/mdq354ISI: 000286673400019PubMedID: 20643864OAI: oai:DiVA.org:uu-149080DiVA: diva2:404013